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BACKGROUND: Intra-tumour genetic heterogeneity has been reported in both leukaemias and solid tumours and is implicated in the
development of drug resistance in CML and AML. The role of genetic heterogeneity in drug response in solid tumours is unknown.
METHODS: To investigate intra-tumour genetic heterogeneity and chemoradiation response in advanced cervical cancer, we analysed
10 cases treated on the CTCR-CE01 clinical study. Core biopsies for molecular profiling were taken from four quadrants of the cervix
pre-treatment, and weeks 2 and 5 of treatment. Biopsies were scored for cellularity and profiled using Agilent 180k human whole
genome CGH arrays. We compared genomic profiles from 69 cores from 10 patients to test for genetic heterogeneity and treatment
effects at weeks 0, 2 and 5 of treatment.
RESULTS: Three patients had two or more distinct genetic subpopulations pre-treatment. Subpopulations within each tumour showed
differential responses to chemoradiotherapy. In two cases, there was selection for a single intrinsically resistant subpopulation that
persisted at detectable levels after 5 weeks of chemoradiotherapy. Phylogenetic analysis reconstructed the order in which genomic
rearrangements occurred in the carcinogenesis of these tumours and confirmed gain of 3q and loss of 11q as early events in cervical
cancer progression.
CONCLUSION: Selection effects from chemoradiotherapy cause dynamic changes in genetic subpopulations in advanced cervical
cancers, which may explain disease persistence and subsequent relapse. Significant genetic heterogeneity in advanced cervical cancers
may therefore be predictive of poor outcome.
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Although screening has reduced cervical cancer rates in the United
Kingdom by nearly 50%, cervical cancer still accounts for 10% of
all cancer cases in women worldwide. The development of cervical
cancer is driven by infection with human papillomavirus (HPV)
(zur Hausen, 1976; Walboomers et al, 1999) through de-regulation
of the crucial p53 and Rb tumour suppressor pathways by the viral
oncoproteins E6 and E7 (Dyson et al, 1989; Band et al, 1991). Loss
of p53 checkpoint function can lead to genomic instability and, in
addition to the initiating virus-driven events, cervical carcinomas
accumulate multiple genomic changes, of which only some are
driver mutations for tumour development (Allen et al, 2000; Lando
et al, 2009).
Prognosis and treatment options for invasive cervical cancer are
currently based on disease stage, which indicates the size and
spread of disease. Five-year survival is stage dependent, ranging
from 80% for stage Ib to 30% for stage IIIb disease (Petignat and
Roy, 2007), and with adenocarcinomas showing lower survival
rates than squamous cell carcinomas (SCC) (Gien et al, 2010).
Cases of stage II disease or higher, and some large stage Ib
tumours, are treated with radiotherapy and concurrent cisplatin
chemotherapy as a radiation sensitiser (chemo-RT) to improve
survival and reduce recurrence (Chemoradiotherapy for Cervical
Cancer Meta-analysis Collaboration, 2010). Advanced stage,
tumour bulk and positive lymph node status are all clinical
predictors of poor outcome. However, there are no known
molecular predictors of response or outcome in cervical cancer.
The common genomic aberrations occurring in cervical cancer,
particularly with respect to stage-specific changes, have been
characterised using classical and array-based cytogenetic techni-
ques. Gain of 3q is associated with the switch from pre-malignant
cervical intra-epithelial neoplasia (CIN) to invasive disease
(Heselmeyer et al, 1996) and with loss of 3p, 11q, 6q and 10q
being the most common change in stage Ib SCC, when the cancer is
still confined to the cervix (Allen et al, 2000). Further gains are
seen in later stages of cervical SCC, most frequently 1q, 5p, 6p and
20 (Heselmeyer et al, 1997). The pattern of losses in more
advanced, stages IIb–IVb, SCC is different from that of stage Ib
disease, with the most common losses on 2q, 3p, 4, 8p and 13q
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s(Heselmeyer et al, 1997). Adenocarcinomas show fewer aberra-
tions on average than SCCs, but share similar gains and losses
(Wilting et al, 2006). The most common changes in adenocarci-
nomas are gain of 3q, 17q, 1 and 11q and loss of 4q, 13q and 18q
(Yang et al, 2001). However, these data are derived from analysing
single samples from multiple cases. It is unknown whether
molecular profiles within individual tumours change with disease
progression and therapy.
Although studies profiling genomic aberrations in cancer
commonly sample a single site at a single timepoint, well-
established evidence shows that tumours may be genetically
heterogeneous. Separation of tumour subpopulations based on
DNA index has shown intra-tumour genetic heterogeneity in
breast cancers, with both ancestral diploid and later aneuploid
clones present in many tumours (Bonsing et al, 2000). More
recently, modern genomic techniques such as high-resolution
array CGH and high-throughput sequencing have shown pre-
existing heterogeneity of chromosome rearrangements and point
mutations in breast cancer that are present at frequencies of up to
13% in the primary tumour (Shah et al, 2009; Navin et al, 2010).
Genetic heterogeneity, which results from divergent evolution
from a single malignant cell, is distinct from polyclonality, in
which multiple cells have independently undergone transforma-
tion. Cervical intra-epithelial neoplasia lesions can be polyclonal,
potentially due to a field effect of HPV infection (Guo et al, 2000).
However, invasive cervical cancer components have been shown to
be monoclonal using integration site of the HPV genome as a
lineage marker (Guo et al, 2000; Ueda et al, 2003). During cancer
progression, further genetic evolution and subsequent divergence
from the monoclonal origin may occur, driven by genomic
instability and high proliferation during tumour growth (Nowell,
1976). The development of intra-tumour genetic heterogeneity
may therefore provide genetic variation allowing selection effects
from chemotherapy or radiation treatment.
Where genetic heterogeneity exists, it is possible that the
subpopulations present will have different levels of intrinsic
resistance to therapy and show differential responses to treatment.
In acute lymphoblastic leukaemias, relapses can be caused by
selection and outgrowth of minor genetic subpopulations present
before treatment (Mullighan et al, 2008) and presumably
intrinsically resistant to therapy. In ovarian cancer the develop-
ment of drug-resistant disease can arise from selection of
pre-existing minor genetic subpopulations following clearance of
a dominant treatment-sensitive population by chemotherapy
(Cooke et al, 2010). As a consequence, intra-tumour genetic
heterogeneity may be both a predictive marker for response
to therapy and a prognostic marker of disease outcome. In the
pre-invasive condition Barrett’s oesophagus, the number of genetic
subpopulations present within dysplastic tissues has prognostic
value, as high levels of heterogeneity are predictive of an increased
risk of progression to oesophageal cancer (Maley et al, 2006). It has
not been established if the degree of heterogeneity predicts
response or treatment resistance in invasive cancers.
We have used array CGH profiling of quadrantic biopsies taken
sequentially from cervical carcinomas before and after treatment
with chemo-RT to test for genetic heterogeneity and in vivo
selection during chemo-RT treatment.
MATERIALS AND METHODS
Primary tumour samples
Samples were obtained from subjects on the CTCR-CE01
prospective clinical study (Zahra et al, 2009), which recruited
19 patients between March 2005 and September 2006 (LREC ID
05/Q0108/25). This work is presented following REMARK guide-
lines (McShane et al, 2005). A flow diagram of patient recruitment
and sample analysis is included (Figure 1A). Patients received
external beam radiotherapy (EBRT) at a dose of 45Gy in 25
fractions over 5 weeks, with weekly cisplatin (40mgm
 2). Four
quadrantic biopsies were collected using a Trucut biopsy needle by
an experienced gynaecological oncologist (RC) at up to three
timepoints: pre-treatment and after weeks 2 and 5 of treatment
(Figure 1B) and snap frozen. Sequential samples were analysed
from the same quadrantic regions so that these were consistent
between timepoints. Following exclusion of patients who dropped
out after collection at a single timepoint (n¼6) or did not receive
chemo-RT (n¼3), 69 samples from 10 cases were evaluable.
Median follow-up time was 51 months (range 41–60). Following
5 weeks of EBRT and cisplatin, all patients subsequently received
brachytherapy.
DNA extraction
Samples were processed using the Qiagen DNeasy Blood and
Tissue kit (Qiagen, Crawley, UK) according to the manufacturer’s
instructions. When biopsies were of sufficient size (longer than
approximately 5mm), a small section was removed from one end
for haematoxylin–eosin staining in order to assess tumour
cellularity. The remaining tissue was digested overnight in
proteinase K and buffer ATL and the DNA purified on a DNeasy
Mini spin column. DNA was eluted in 200ml buffer AE and the
19 Patients
recruited to CE01
3 Patients
treated surgically
6 Patients withdrew
after pre-treatment biopsies
16 Patients received
chemoradiotherapy
10 Patients had biopsies
taken at 2+ timepoints
(69 samples)
4 Cases excluded
due to low cellularity
6 Cases provided at least
one aberrant profile by
array CGH
6 Cases analysed for intra-
tumour genetic heterogeneity
EBRT
Cisplatin
EBRT
Cisplatin
Weeks
0 2 5
4
3
1
2
41
2 3
41
32
Timepoint
Region
A
B
Figure 1 (A) Flow chart of patient recruitment and sample collection.
(B) Design of the CTCR-CE01 clinical study. Samples were collected
at three timepoints (weeks 0, 2 and 5) pre-, during and post-
chemoradiotherapy. At each timepoint, samples were collected from up
to four regions of the cervix (1–4).
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quality was assessed by nanodrop (Thermo Scientific, Wilmington,
MA, USA) and samples with 260/280 ratios o1.7 were cleaned up
by sodium acetate/ethanol precipitation. Human papillomavirus
testing was carried out using the Linear Array HPV genotyping test
(Roche Diagnostics, West Sussex, UK).
Array CGH
Array CGH was carried out by Oxford Gene Technology (Oxford,
UK) on the Agilent SurePrint G3 Human Catalog 4x180k array
CGH platform. Data analysis was carried out in-house using the
Bioconductor packages snapCGH, DNAcopy and CGHcall. The
arrays were median normalised and segmented using the circular
binary segmentation algorithm (Olshen et al, 2004). Cellularity was
assessed by histopathology and by probability analysis using
CGHcall implemented in R. Amplification was defined as regions
with a log ratio 41.5 and homozygous deletion as log ratio o 1.5.
Array CGH data have been uploaded to the GEO database with
accession number GSE21025.
RESULTS
To investigate genomic markers of response, we analysed with
array CGH sequential biopsies from 10 cases of cervical carcinoma
taken before and during chemo-RT in the CTCR-CE01 study
(Figure 1). Biopsies were taken from each quadrant of the cervix
before treatment, and after weeks 2 and 5 of chemo-RT. Six
patients declined biopsies at week 2, meaning that samples were
only available for four patients at this timepoint. Where possible,
the same core biopsy was used for histopathological assessment of
tumour cellularity (n¼24) and array CGH (n¼69) (Table 1). The
ability to detect abnormal tumour profiles by array CGH was
correlated with tumour cellularity as determined by histopatholo-
gical examination (Table 1 and Supplementary Figure 1).
Four cases, CE01-03, -04, -10 and -12, had normal profiles in all
quadrants assessed by array CGH before treatment (Table 1).
Histopathological examination of stained sections from these
samples showed tumours with a low percentage of tumour cells
and a high stromal cell content (Supplementary Figure 2). These
cases were therefore not analysed further. Six cases had abnormal
array CGH profiles in at least one biopsy at presentation (Table 1).
Genetic heterogeneity arises from monoclonal origins
through divergent evolution
In order to investigate sequential changes, we first compared array
CGH profiles between quadrants and timepoints for each case to
test for treatment-related change. Each case showed at least one
genomic aberration shared between all aberrant profiles, consis-
tent with a monoclonal origin (Table 2 and data not shown).
However, comparison between quadrants at a single timepoint and
between timepoints showed differences for three cases (CE01-02,
-09 and -13) that suggested more than one population of tumour
cells was present within the tumour. These cases had marked
genetic heterogeneity, with up to 17 aberrations per tumour
differing in pairwise comparisons (Table 2 and Figure 2). Three
cases, CE01-01, -06 and -14, were genetically homogeneous. At
week 0, cases CE01-01 and -06 had tumour cells and an abnormal
genomic profile confined to only a single region of the cervix.
These tumour cells did not persist by the end of week 5 of
treatment (Table 1) and were not replaced with any other genetic
subpopulation. Case CE01-14 had two quadrants with identical
complex abnormal array CGH profiles (Supplementary Figure 3),
which also were not present by week 5.
Minor genetic subpopulations show differential responses
to chemo-RT
We next investigated whether, in the three genetically hetero-
geneous cases, different genetic subpopulations within each
tumour showed differential responses to chemo-RT. For cases
CE01-02, -09 and -13, we produced phylogenetic trees based on the
genomic aberrations present according to the method of Navin
et al (2010) (Figure 3). An artificial normal consisting of a diploid
genome was included to give perspective on genetic distance.
The phylogeny trees for cases CE01-02, -09 and -13 showed
that each of these three cases contained multiple distinct tumour
subpopulations (Table 2 and Figure 3). For case CE01-02,
abnormal profiles were present at weeks 0 and 2, but no
abnormalities were present at week 5. Samples clustered into
pre- and post-treatment (week 2) profiles (Figure 3A). Profiles of
pre-treatment (n¼3) all showed gain of 3q, loss of 4q and
amplicons on 17q, but differed with subclonal changes on
chromosomes 1, 3, 11, 17, 19 and X (Table 2 and Figure 2). After
week 2 of therapy, a new clonal population appeared in all four
quadrants that retained 3q gain, but did not have the rearrange-
ments of 4q or amplification on 17q. Given the magnitude of the
amplification and consistency of replacement in at least three
quadrants, this observation is highly unlikely to reflect a sampling
artefact. This new population showed subclonal changes on
chromosomes 17, 19 and X (Table 2 and Figure 2).
In case 13, two distinct clones were initially present, with copy
number aberrations on chromosomes 10, 15 and 19 defining one
lineage (quadrants 1 and 2) and aberrations on chromosomes 16, 18,
19, 20 and X defining the other (quadrants 3 and 4) (Figure 3B). By
Table 1 Clinical characteristics for 10 cases of cervical cancer from the CTCR-CE01 clinical study
Study
number Age Type Stage LN
Reg
%
HPV
type
Abnormal
array
CGH
week 0
H&E %
tumour
at week 0
Abnormal
array
CGH
week 1
H&E %
tumour
at week 1
Abnormal
array
CGH
week 5
H&E %
tumour
at week 5
Survival
(months)
Cause of
death
CE01-01 45 SCC IIb Neg 76 16 F, F, F, T 0,  ,0 ,  F, F,  ,F  ,  ,  ,   F, F, F, F  ,  ,1 ,o1 460
CE01-02 33 SCC IIb Neg 77 6, 45  ,T ,T ,T  ,  , 85,   T, T, T, T  , 10, 40,   F, F, F,    ,  ,  ,   20 Local recurrence
CE01-03 49 Adeno Ib2 ND 88 Neg  ,F ,F ,F  , 10, 0, 30  ,F ,F ,F  ,  ,  ,    ,F ,F ,F  ,0 , , o1 7 Local recurrence
CE01-04 55 SCC IIb ND ND Neg F, F, F, F  ,  , 50,    ,F ,F ,F  ,  ,  ,   F, F, F, F  ,0 , ,   6 Local recurrence
CE01-06 55 SCC IIb ND 57 16 F,  ,T ,F  ,  ,  ,    ,  ,  ,    ,  ,  ,   F,  ,F ,F  ,  ,  ,0 456
CE01-09 33 SCC IIIb Pos 41 ND T,  ,T ,   ,  ,  ,    ,  ,  ,    ,  ,  ,   T,  ,  ,   8,  ,  ,   7 Local recurrence
CE01-10 30 SCC IIb Neg 100 18 F,  ,  , F 10,  ,  ,5  ,  ,  ,    ,  ,  ,   F,  ,  ,F  ,  ,  ,   451
CE01-12 67 SCC IIb Pos 67 16 F,  ,  , F 40,  ,  ,2 0  ,  ,  ,    ,  ,  ,   F,  ,  ,F  ,  ,  ,5 450
CE01-13 48 Adeno IIb Neg 36 18 T, T, T, T 40,  ,  ,    ,  ,  ,    ,  ,  ,   F, T,  ,F  ,  ,  , 3 8 Liver metastasis
CE01-14 27 SCC IIb Neg 81 16 T,  ,T ,  70,  ,  ,    ,  ,  ,    ,  ,  ,   F,  ,F ,   ,  ,  ,   441
Abbreviations: SCC¼squamous cell carcinoma; adeno¼adenocarcinoma; LN¼lymph node status; Reg %¼percentage regression according to MRI; ND¼not done; F¼false;
T¼true. Array CGH and H&E data are given for quadrants 1–4 at each timepoint. Note: Not all regions at each timepoint had sufficient material for histopathological assessment
and not all tumours had sufficient material for HPV tying.
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previously dominant in quadrants 3 and 4 (Figure 3B).
Case CE01-09 also showed two clones with markedly divergent
genomic profiles at week 0 (Figure 3C), with a near-normal profile
showing loss of chromosome 19 and complex rearrangement
of 11q (quadrant 1) and a highly aberrant population with
17 additional copy number aberrations (quadrant 3) (Table 2 and
Figure 3C). The relatively normal genomic profile in quadrant 1
suggested that the biopsy had high stroma content allowing
detection of the highest magnitude changes. Tissue was not
available for cellularity scoring of quadrant 1 at week 0. However,
in the highly abnormal quadrant, the highest magnitude changes
observed were high-level gain of 5p and 11q, along with the loss of
10q and distal 11q. Of these, only the 11q gain was seen in the
quadrant 1 profiles; therefore, comparison of the quadrants
suggests that these are divergent subpopulations, and the simpler
karyotype may represent an ancestral clone containing the earliest
events in carcinogenesis. At week 5 of therapy, residual disease
persisted in quadrant 1 and had the same profile as pre-treatment.
However, quadrant 3 at week 5 showed no residual tumour cells by
histopathology and no aberrations on array CGH (Table 1).
Persistent disease following chemo-RT
Only two cases, CE01-09 and -13, showed abnormal array CGH
profiles by the end of 5 weeks of chemo-RT. Cases CE01-09 and -13
had poor response to treatment and persistent disease, showing
regression of only 41% and 36%, respectively, by MRI and with
Table 2 Heterogeneous and common rearrangements and breakpoints
found in cases CE01-02, -09 and -13
Case Chr. Position Type Status Week 0 Week 2 Week 5
02 1 108.1–119.9 Loss Het 2, 3 1, 3, 4
02 1 q arm Gain Het 2, 3 1, 2, 3, 4
02 3 55.8–cen Loss Het 2, 3 1, 2, 3, 4
02 3 153.8-q tel Gain Hom
02 4 86.6–q tel Loss Het 2, 3, 4
02 11 74.7–85.3 Gain Het 3, 4
02 11 85.3–q tel Loss Het 4
02 11 94.8–q tel Loss Het 2, 3 1, 2, 3, 4
02 17 28.5–29.7 Amplicon Het 2, 3, 4
02 17 34.9–35.3 Amplicon Het 2, 3, 4
02 17 43.9–q tel Gain Het 4
02 17 47.0–q tel Gain Het 4
02 17 Whole chr Gain Het 2, 3 1
02 19 p tel-14.5 Gain Het 1, 2
02 19 9.5–14.5 Gain Het 3, 4
02 19 Whole chr Loss Het 3, 4
02 X Whole chr Gain Het 2, 3 1
13 3 141.6-q tel Gain Hom
13 4 167.4–170.1 Loss Hom
13 9 p tel–13.2 Loss Hom
13 10 Whole chr Gain Het 1, 2
13 15 25.0–80.7 Loss Het 3 2
13 15 25.0–45.7 Loss Het 1, 2, 4
13 15 45.7–46.2 Gain Het 1, 2, 4
13 15 46.2–60.7 Loss Het 1, 2, 4
13 15 60.7–77.7 Gain Het 1, 2
13 15 60.7–61.7 Gain Het 4
13 15 75.9–77.7 Gain Het 4
13 15 77.7–77.9 Loss Het 1, 2, 4
13 15 77.9–78.1 Gain Het 1, 2, 4
13 15 78.1–81.0 Loss Het 1, 2, 4
13 15 81.0–89.3 Gain Het 1, 2, 4
13 15 89.3–q tel Loss Hom
13 16 cen–q tel Loss Het 3, 4 2
13 18 23.2–q tel Loss Het 3, 4 2
13 19 p tel–cen Gain Het 1, 2
13 19 cen–51.5 Further gain Het 1, 2
13 19 cen–q tel Gain Het 3, 4 2
13 20 20.5–22.1 Loss Het 3, 4 2
13 X 65.0–q tel Loss Het 3, 4 2
09 2 p tel–180.6 Gain Het 3
09 5 p tel–5.1 Gain Het 3
09 5 5.1–cen Further gain Het 3
09 5 cen–q tel Loss Het 3
09 6 p tel–35.6 Gain Het 3
09 7 p tel–2.3 Gain Het 3
09 7 2.3–cen Loss Het 3
09 8 Whole chr Gain Het 3
09 10 p tel–27.8 Loss Het 3
09 10 87.3–q tel Loss Het 3
09 11 75.1–98.9 Gain Hom
09 11 98.9–104.4 Further gain Hom
09 11 104.4–q tel Loss Hom
09 16 p tel–cen Loss Het 3
09 16 80.3–q tel Gain Het 3
09 18 Whole chr Loss Het 3
09 19 p tel–cen Loss Het 3
09 19 Whole chr Loss Het 1 1
09 21 p tel–33.5 Loss Het 3
09 22 Whole chr Loss Het 3
09 X Whole chr Gain Het 3
Abbreviations: tel¼telomere; cen¼centromere; het¼heterogeneous; hom¼
homogeneous. Heterogeneous aberrations are listed according to the quadrants in
which they are present for each timepoint.
A
B
C
Case 02
1
3
4
11
17
19
X
10
15
16 18 19 20
X
Case 13
Case 09
2
5
6
7 8
10
16 18 19
21 22
X
Figure 2 Chromosomes with subclonal differences within cases. The copy
number aberrations found in different subpopulations are shown on the right
of each ideogram. (A)C E 0 1 - 0 2 ,( B)C E 0 1 - 1 3a n d( C)C E 0 1 - 0 9 .R e d–l o s s ;
green – gain; yellow – amplification; and grey – no copy number change.
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shigher proportions of residual tumour cells on histopathological
examination at week 5. These patients also had the shortest
survival times of 7 and 8 months, respectively (Table 1). In both
cases, residual disease consisted of one of the genetic subpopula-
tions detectable before therapy (Figure 3). Case CE01-09 sub-
sequently died from local recurrence, while case 13 died from
liver metastases (Table 1). Decreasing tumour cellularity at later
timepoints and restoration of normal genomic profiles in the
remaining four cases, CE01-01, -02, -06 and -14, was correlated
with high percentage tumour regression as assessed on MRI
(Table 1), indicating good response to chemo-RT and a low
percentage of residual tumour cells.
As different subpopulations appeared to show differential
responses to chemo-RT, we next investigated which events might
be involved in the preferential survival of genetic subpopulations.
Case CE01-02 showed heterogeneity of rearrangements on
chromosomes 1, 3, 4, 11, 17 and 19. The phylogeny analysis
predicted that two lineages diverged from a common ancestor,
with the pre-treatment population acquiring additional events
including loss of 4q, from 86.6Mb to the telomere, and
amplification on 17q (Table 2 and Figure 3A). Amplicons included
28.5–29.7 and 34.9–35.3Mb (Table 2). The highest-level gain was
at 28.5–29.3Mb, containing only the first exon of the extremely
large ACCN1 gene, but the 34.9–35.3Mb amplicon contained
multiple genes including Her2 (ERBB2). In contrast, there were no
events common to all week 2 subclones and absent from all week 0
subpopulations. This suggests that either the loss on 4q or the 17q
amplicons may have been involved in the differential response of
genetic subpopulations to chemo-RT in this case.
For cases CE01-09 and -13, there were multiple genomic regions
that varied between the distinct genetic lineages, providing an
extensive list of candidates for differential response to therapy
(Table 2 and Figure 3). Some of the regions were large, in several
cases consisting of a whole chromosome arm, and therefore
contain many genes as potential drivers. Of the cases that were
homogeneous (CE01-01, -06 and -14), but responded well
to therapy, all three shared loss of 5q, a rearrangement also seen
in the treatment-sensitive subpopulation in case CE01-09. In
addition, cases 01 and 14 shared 5p gain, also seen in the sensitive
subpopulation of case CE01-09, with the minimum common
region of gain across all cases encompassing the first 35.5Mb of 5p
(Supplementary Figure 4). Rearrangement of chromosome 5 may
therefore be associated with good response to chemo-RT.
Inferring early driving events
Given the phylogenetic relationships for each tumour, we were able
to predict the order in which various genomic rearrangements
occurred (Figure 3). As subpopulations only share events that
occurred before divergence, we hypothesised that the earliest
events would be those changes common to all subpopulations
within a tumour, and that the more distantly related the
subpopulations that are profiled, the earlier the events found in
the overlap between them. In both cases, CE01-02 and -13 early
events included 3q gain, from 153.8 Mb to the telomere and from
141.6Mb to the telomere, respectively (Table 2), an event that has
previously been identified as one of the first changes seen in the
progression from pre-malignant lesion to carcinoma (Heselmeyer
et al, 1996). Case CE01-13 additionally contained loss of 9p and
15q and gain of a small, 2.7Mb, region of 4q as very early events.
The pattern of chromosome 11 rearrangement in case CE01-02
suggested that an initial loss event from 94.8Mb to the telomere
preceded divergence and was followed by further independent
rearrangements of 11q in the separate lineages (Table 2).
Case CE01-09 had rearrangements of chromosome 11, gain of
75.1–104.4Mb and loss of 104.4-telomere, as the early events.
These aberrations are therefore likely driver events in the
carcinogenesis of these tumours.
Case 02 Multiple
subclonal
differences
1
4
3
2
Diploid
Gains 1q, 3q Losses 3p, 11q
2
3
4
Loss 4q
Amplicons 17q
0.2
4
3
1
2
4
32
1 4
3 2
1
Case 13 Diploid
Losses 16q, 18q,
20p, Xp
Gain 19q 3
2
4
Gain 3q Losses 4q, 9p, 15q
2 1
0.2
Gains 10, 19p, 19q
1
2
1
2
4
3
1
2
4
3
4
3
Case 09 Loss 19
1
1
0.2
Multiple
copy number
aberrations
Diploid
11q rearrangement
4
32
14
32
14
32
1
3
A
B
C
Figure 3 Phylogeny analysis of cases (A) CE01-02, (B) CE01-13 and
(C) CE01-09. Branch length is proportional to evolutionary distance and a
normal diploid genome is included for perspective. Black boxes – week 0;
no box – week 2; and black outline – week 5. Underneath each
evolutionary tree are maps of subpopulation distribution over time. Blue
and red shading represents genetically distinct subpopulations, white
indicates that no sample was available for a region and grey indicates
that the array CGH profile was normal.
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The CE01 study was designed to detect imaging (Zahra et al, 2009)
and genomic biomarkers of response by sequential analysis of
disease at weeks 0, 2 and 5 of treatment. A unique strength of the
design was the collection of multiple, spatially separate, biopsies at
each timepoint. To our surprise, this revealed both spatial genetic
heterogeneity within a proportion of tumours and a differential
effect of chemo-RT on different genetic subpopulations. The cases
analysed showed copy number aberrations that were representa-
tive of larger series of invasive cervical cancers. We observed the
presence of known common changes on many chromosomes,
including most frequently chromosomes 3, 5 and 11 (Heselmeyer
et al, 1997; Allen et al, 2000).
Carcinogenesis is a Darwinian evolutionary process at the
single-cell level, with acquired genetic aberrations, which drive
tumour progression being selected for, along with multiple
passenger events (Nowell, 1976). Intra-tumour genetic hetero-
geneity could reflect waves of clonal expansion, competing
populations evolving in parallel or co-operation between tumour
subpopulations (Merlo et al, 2006). Theoretically either genetic
heterogeneity or genetic homogeneity could be predictive of poor
outcome, depending on the underlying biological processes.
Genetic homogenisation may occur in tumours through expansion
of an extremely aggressive subclone, leading to poor prognosis.
Alternatively, extensive genetic heterogeneity may increase the
likelihood of resistance evolving and therefore predict increased
risk of relapse (Maley et al, 2006). In the pre-cancerous lesion
Barrett’s oesophagus, genetic heterogeneity predicts progression
oesophageal cancer (Maley et al, 2006). However, the relationship
between heterogeneity and outcome has never been tested in
invasive cancer. Interestingly, in our study, patients with homo-
geneous tumours showed long survival times of 460, 456 and
441 months for cases CE01-01, -06 and -14, respectively. In
contrast, genetically heterogeneous tumour cases had survival of
20, 7 and 8 months for CE01-02, -09 and -13, respectively.
Although the limited number of patients precludes statistical
significance, this is consistent with genetic heterogeneity predict-
ing poor outcome in advanced cervical cancer.
Case CE01-14 had the most complex array CGH profile observed
in this study, with copy number aberrations on every chromosome
apart from 1, 6, 10 and 21. However, this tumour was
homogeneous. This suggests that although there is variation in
both the numbers of genomic aberrations and the degree of
heterogeneity within cervical tumours, heterogeneity is not simply
a function of genetic instability.
Intra-tumour genetic heterogeneity could encompass both
driver and passenger mutations (Merlo et al, 2006). Interestingly,
heterogeneous regions included some known regions of recurrent
gain and loss, such as 18q loss in adenocarcinoma case CE01-13
and 5p gain in SCC case CE01-09, which are likely driver events.
Other potentially important driving events, such as the Her2
(ErbB2) amplification in case CE01-02, showed heterogeneity, and
clones with and without this event showed differential responses to
chemo-RT. Although the role of Her2 in cervical cancer remains
controversial, Her2 amplification has been reported in up to 14%
of cervical carcinomas (Mitra et al, 1994), and increased Her2
expression can correlate with increased overall survival rates
following both radiotherapy and chemo-RT (Lee et al, 2005;
Yamashita et al, 2009).
The three heterogeneous cases in this study (CE01-02, -09 and -13)
relapsed and died from recurrent disease. Within these hetero-
geneous tumours, different genetic subpopulations showed differ-
ential responses to treatment. In cases CE01-09 and -13, two
distinct subpopulations were present before treatment, but only
one remained detectable by array CGH following chemo-RT.
Persistence of an abnormal genomic profile correlated with clinical
parameters of poor response, including low percentage tumour
regression and low Ktrans values from MRI and functional
MRI parameters (Zahra et al, 2009). These observations may
reflect clearance of treatment-sensitive regions of the tumour, but
persistence of tumour volume consisting of intrinsically resistant
cells, which subsequently give rise to disease recurrence. Case
CE01-09 relapsed with local recurrence, consistent with tumour
cells surviving chemo-RT at the primary site. However, case
CE01-13 died from liver metastases, requiring tumour cells to have
survived systemic cisplatin chemotherapy, although they may have
established as distant micrometastases before radiotherapy at the
primary site. Alternatively, the population persisting after therapy
may subsequently have metastasised to the liver, causing relapse.
Case CE01-02 relapsed with local recurrence and had an
intermediate survival time of 20 months. Current clinical
prognostic indicators for this case, low-stage (IIb), negative lymph
node status and high percentage tumour regression (77%), were
good. However, we found evidence of intra-tumour genetic
heterogeneity and an intrinsically more resistant minor subpopu-
lation. The disease profiled at weeks 0 and 2 was genetically
distinct, but both genetic subpopulations appeared to regress
after 5 weeks of therapy. This implies that the genetic changes seen
at week 2 represent differential responses between two distinct
subpopulations that co-existed before treatment. If the new
genomic profile had arisen and reached detectable levels in all
quadrants within 2 weeks of therapy, this would require an
extremely high proliferation rate under strong selective pressure.
This is inconsistent with the observed regression of this
subpopulation after 5 weeks of chemo-RT. It therefore seems
likely that clearance of the dominant population at presentation by
initial chemo-RT allowed profiling of a subpopulation that was
present throughout the tumour at levels below the threshold of
detection before treatment.
Although the spatial replacement observed in case 02 seems best
explained by differential survival of two pre-existing subpopula-
tions, in case CE01-13 the spatial replacement observed during
therapy could represent either differential survival or repopulation
of the cleared regions of tumour by an intrinsically resistant
subpopulation. In case CE01-13, replacement was seen after
completion of 5 weeks of therapy. Repopulation during chemo-RT
requires expansion under the selective pressure of chemo-RT
consistent with a high level of intrinsic resistance to therapy.
Increased proliferation on treatment is observed in cervical cancer
and consistently high proliferation after 2 weeks of therapy is
associated with high risk of disease progression (Durand and
Aquino-Parsons, 2004). However, it is unknown if repopulation is
associated with changes in genomic profile.
Although residual disease in case CE01-02 could not be detected
by array CGH after 5 weeks of chemo-RT, subsequent relapse with
local recurrence implies a failure to clear all disease from the
primary site. Given the intermediate survival for case CE01-02
(20 months) and short survival for cases CE01-09 and -13 (7 and 8
months), which had detectable residual disease, it is possible that
intrinsically resistant subpopulations made up a smaller propor-
tion of the tumour mass in case CE01-02 than in cases CE01-09
and -13. Heterogeneity before and during treatment may therefore
indicate poor outcome, while levels of persistent disease after
therapy may be an indicator of time interval to relapse.
Profiling divergent subpopulations allows the identification of
early events, which predate divergence (Cooke et al, 2010). Using
this approach, gain of 3q was a confirmed early event in this study,
occurring early in 2/3 heterogeneous cases. This supports previous
data placing 3q gain at the transition from CIN to invasive
carcinoma (Heselmeyer et al, 1996). Loss of 11q was also a
recurrent early event in our study and is known to be one of the
most common changes in stage Ib disease (Allen et al, 2000).
Although there are significant difficulties in obtaining multiple
samples from patients during treatment, our data emphasise
how informative they may be in understanding the evolution of
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resistance. Using quadrantic biopsies, we showed the presence of
intra-tumour genetic heterogeneity in our limited series of cervical
cancers, but we may well have underestimated the level of
heterogeneity within each tumour as our results depend on the
sensitivity of array CGH in whole tissues. Microscopic hetero-
geneity may be present as has been suggested for breast tumours
(Navin et al, 2010). Future studies should evaluate flow sorting or
microdissection to remove stromal contamination, and address
microscopic heterogeneity.
There is increasing evidence that many solid tumour
types, including breast (Navin et al, 2010) and ovarian cancers
(Khalique et al, 2007), show significant genetic heterogeneity.
We have recently shown in ovarian cancer that post-treatment
clones are significantly divergent from pre-treatment clones,
suggesting that heterogeneity may be relevant for both initial
treatment response and the subsequent likelihood of relapse
and the emergence of resistance (Cooke et al, 2010). Taken
together, the presence of subpopulations with differing levels of
intrinsic resistance to therapy within some advanced cervical
tumours and the poor outcome in these cases suggests a similar
role for intra-tumour genetic heterogeneity in cervical cancers.
If this is indeed the case, intra-tumour genetic heterogeneity
in advanced cervical cancers may have both predictive and
prognostic value.
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